// App-Quantinova.ai

44 : Hexyl-benzyl-biguanide (HBB) potently and selectively inhibits CYP3A4 epoxygenase activity and inhibits EET stabilization of mitochondrial respiration in ER+HER2- breast cancer cells, inducing glycolysis and pyruvate biosynthesis

Researchers

Presenter

  • Zhijun Guo

Principal Investigators

  • Eric Hanse

  • Xia Zhang

  • Ilia Denisov

  • Ting-Lan Chiu

  • Rebecca Cuellar

  • Christian Torres

  • Julia Wulfkuhle

  • Emanuel Petricoin

  • Qing Cao

  • Haitao Chu

  • Beverly Norris

  • Robert Schumacher

  • Ameeta Kelekar

  • Ian Blair

  • Jorge Capdevila

  • John Falck

  • Thomas Poulos

  • Steven Sligar

  • Gunda Georg

  • Elizabeth Amin

  • David A. Potter

Medical Centers

  • University of Minnesota Masonic Cancer Research Center, Minneapolis, MN

  • University of California, Irvine, Fullerton, CA

  • University of Illinois at Urbana-Champaign, Urbana, IL

  • University of Minnesota, Minneapolis, MN

  • University of Minnesota, Minneapolis, MN

  • George Mason University, Manassas, VA

  • University of Pennsylvania, Philadelphia, PA

  • Vanderbilt University, Nashville, TN

  • The University of Texas Southwestern, Dallas, TX

  • University of Illinois at Urbana-Champaign, Urbana, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Tuberculosis

  • Solid malignancies

Biomarkers

  • Pyruvate Kinase M1/2

  • Cytochrome P450 Family 3 Subfamily A Member 4

  • erb-b2 receptor tyrosine kinase 2

  • Epoxyeicosatrienoic acids

Drug/Treatment

  • Metformin Hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved